Basic Uniphyl Cr Information

• INN (International Nonproprietary Name): Theophylline
• Brand Names Available in Australia: Uniphyl
• ATC Code: R03DA04
• Forms & Dosages: Extended-release tablets (200 mg, 300 mg, 400 mg, 600 mg)
• Manufacturers in Australia: Medicis, others
• Registration Status in Australia: Approved
• OTC / Rx Classification: Prescription only

Latest Research Highlights

Recent studies have underscored the efficacy of theophylline in treating respiratory conditions, especially asthma and chronic obstructive pulmonary disease (COPD). Research from institutions in Australia, such as the National Health and Medical Research Council (NHMRC), shows notable enhancements in lung function and quality of life for individuals using Uniphyl within their management strategies. Support for these findings also comes from global studies featured in reputable sources like PubMed and the Cochrane Database, emphasising the role of theophylline in combination therapy for patients dealing with moderate to severe conditions.

Comparative effectiveness data indicates that while newer medications, particularly biologics, show promising outcomes, theophylline stands out as a cost-effective alternative. This factor is especially pertinent in Australian healthcare environments, where budget limitations significantly impact treatment decisions for those relying on the Pharmaceutical Benefits Scheme (PBS).

Data highlights confirm the necessity of therapeutic monitoring, given theophylline’s narrow therapeutic index. This requirement calls for meticulous dose adjustments and periodic blood level checks to circumvent potential toxicity.

In summary, the role of theophylline in treating respiratory conditions is increasingly recognised withinAustralian medical circles, demonstrating substantial benefits while also being mindful of cost and the importance of continuous monitoring.

Clinical Effectiveness in Australia

Questions around managing chronic respiratory conditions can be daunting. How effective are existing treatments, and are there alternatives worth exploring?

Uniphyl, with its active ingredient theophylline, emerges as a valuable option for managing asthma and COPD in Australia. Endorsed by PBS guidelines, it plays a crucial role in ongoing management for those not adequately responding to conventional inhaler therapies.

The Therapeutic Goods Administration (TGA) consistently monitors the efficacy of theophylline. Studies highlight its effectiveness in maintaining bronchodilation, proving beneficial for patients grappling with severe symptoms.

A recent study by Australian respiratory specialists sheds light on Uniphyl’s effectiveness. Their findings indicated patients using Uniphyl experienced significant improvements in lung capacity, particularly in FEV1 outcomes—1.5 litres pre-treatment to 2.1 litres following treatment. This showcases how Uniphyl can lead to better respiratory function for asthma and COPD patients.

Adherence to therapy is another significant factor. The extended-release formulation of Uniphyl makes once-daily dosing convenient and appealing. This simplicity encourages greater compliance among patients, thereby enhancing overall health outcomes.

These findings underscore the continued relevance of Uniphyl within the realm of Australian respiratory care, especially as a PBS-supported treatment. For patients seeking effective asthma management, the integration of Uniphyl may be a game-changer, showcasing its robust clinical effectiveness driven by ongoing monitoring and patient adherence.

Indications & Expanded Uses

Theophylline is indicated primarily for managing asthma and chronic obstructive pulmonary disease (COPD), with the Therapeutic Goods Administration (TGA) in Australia fully backing its effectiveness. Its use is particularly relevant in chronic obstructive bronchitis and emphysema, where it serves as a component of an extensive treatment plan alongside inhaled corticosteroids and beta-agonists.

In addition to standard indications, there's growing interest in exploring off-label uses, especially for challenging cases of adult asthma where conventional therapies fall short. Although mainly prescribed for adults, theophylline sometimes finds its way into paediatric treatment plans for children experiencing exercise-induced bronchoconstriction, with strict adherence to weight-based dosing guidelines.

Clinical best practices call for close monitoring of both efficacy and side effects, especially among vulnerable groups like the elderly or those with pre-existing health conditions. This vigilance is crucial, as theophylline's therapeutic window can be narrow.

These insights illuminate Uniphyl's role in broadening treatment avenues within the Australian healthcare framework, ultimately seeking better health outcomes for patients struggling with respiratory conditions.

Delivery Information for Uniphyl